Project Twenty21 is a registry aiming to monitor the health outcomes of 20,000 patients using cannabis based medicinal products (CBMPs), creating the largest body of evidence in Europe for the safety and efficacy of CBMPs. Drug Science hope that the findings of Project Twenty21 will provide evidence for NHS funding where the benefits of treatment with medicinal cannabis is proven to outweigh the potential risks.
This real-world registry aims to target the following indications:
- Anxiety Disorder
- Chronic Pain
- Multiple Sclerosis (MS)
- Post-Traumatic Stress Disorder (PTSD)
- Substance Use Disorder (as a harm reduction strategy)
- Tourette’s Syndrome
In June 2020, the Project Twenty21 team commenced beta testing of the patient pathway and opened up access to one clinic (Medical Cannabis Clinics) for 100 patients. This was required to ensure that we could overcome any barriers to the patient’s journey through the T21 process. We have also increased the number of products that are on our formulary and I would like to thank our licensed producer partners, for all their support.
The Twenty21 team has created an animation explaining the process and below you will find a patient pathway to help you navigate the project. Please remember that new clinics will come on board as the project progresses, meaning that there will be more options available to patients in the future. So if the available clinics do not suit your needs, please register for our project updates to remain informed of how the project is developing. Lastly, as more clinics join the project, there will be more competition so hopefully, the price of consultation will drop further
